Charles Sternberg, Associate Editor05.16.22
Texas Medical Center (TMC) has announced a strategic partnership with Enterprise Ireland, the Irish trade and innovation agency to provide gateway opportunities for Irish companies, entrepreneurs, researchers, clinicians, and industry partners to collaborate with Texas Medical Center to solve global health challenges.
Focused on advancing health and life science through commercialization, innovation and research, the partnership is designed to bolster collaboration and improvement of patient health and care experience through innovative medical devices, digital health solutions, and therapeutics. Research collaboration will focus on identifying opportunities for clinical research and clinical trial activities.
“The breakthrough technology and entrepreneurship that is coming out of Ireland is truly impressive, and the TMC team is thrilled to be in Ireland today to solidify our partnership,” said William McKeon, president and CEO of Texas Medical Center. “The past two years has shown the importance of collaboration at a global scale, and we are eager to start our work with Enterprise Ireland’s team to further global innovation and research.”
Irish Deputy Prime Minister Leo Varadkar TD said, “Years of investment by Government and industry has created a concentrated community of innovation and expertise within Ireland that is breaking new ground and making a major contribution to international healthcare. Today’s announcement by Texas Medical Center and Enterprise Ireland is a very positive development and will drive further integration and opportunities to bring Irish healthcare innovation to the world.”
“The size, scale and reputation of Texas Medical Center brings new opportunities for Irish companies to innovate and scale and enter the US market,” commented Leo Clancy, CEO of Enterprise Ireland. “I am delighted to officially launch this partnership with TMC. Enterprise Ireland places a strong focus on driving innovation in the medtech industry and facilitating successful partnerships between Irish companies and influential global healthcare systems.”
Over the past few months, TMC has worked with LifeLet Medical, a start-up company from Galway, Ireland, who is developing a novel biomimetic leaflet material for heart valve replacements. Lifelet is part of TMC’s HealthTech Accelerator program and is supported by Enterprise Ireland. High Potential Start-Ups, InVera Medical and Aurigen Medical are also past participants of the Health Tech Accelerator Program. LifeLet Medical and Aurigen Medical have also been awarded collaborative funding under the Irish government’s Disruptive Technologies Innovation Fund administered by Enterprise Ireland.
TMC’s BioBridge program facilitates the exchange of ideas and research at a global scale to better the patient experience and provide groundbreaking solutions for complex health care problems. The TMC I Ireland BioBridge is TMC’s fourth international partnership. Other global partners include Australia, Denmark and the United Kingdom. Over 80% of TMC Innovation’s current HealthTech Accelerator cohort is composed of international companies, showing the reach of TMC’s international partnerships.
Focused on advancing health and life science through commercialization, innovation and research, the partnership is designed to bolster collaboration and improvement of patient health and care experience through innovative medical devices, digital health solutions, and therapeutics. Research collaboration will focus on identifying opportunities for clinical research and clinical trial activities.
“The breakthrough technology and entrepreneurship that is coming out of Ireland is truly impressive, and the TMC team is thrilled to be in Ireland today to solidify our partnership,” said William McKeon, president and CEO of Texas Medical Center. “The past two years has shown the importance of collaboration at a global scale, and we are eager to start our work with Enterprise Ireland’s team to further global innovation and research.”
Irish Deputy Prime Minister Leo Varadkar TD said, “Years of investment by Government and industry has created a concentrated community of innovation and expertise within Ireland that is breaking new ground and making a major contribution to international healthcare. Today’s announcement by Texas Medical Center and Enterprise Ireland is a very positive development and will drive further integration and opportunities to bring Irish healthcare innovation to the world.”
“The size, scale and reputation of Texas Medical Center brings new opportunities for Irish companies to innovate and scale and enter the US market,” commented Leo Clancy, CEO of Enterprise Ireland. “I am delighted to officially launch this partnership with TMC. Enterprise Ireland places a strong focus on driving innovation in the medtech industry and facilitating successful partnerships between Irish companies and influential global healthcare systems.”
Over the past few months, TMC has worked with LifeLet Medical, a start-up company from Galway, Ireland, who is developing a novel biomimetic leaflet material for heart valve replacements. Lifelet is part of TMC’s HealthTech Accelerator program and is supported by Enterprise Ireland. High Potential Start-Ups, InVera Medical and Aurigen Medical are also past participants of the Health Tech Accelerator Program. LifeLet Medical and Aurigen Medical have also been awarded collaborative funding under the Irish government’s Disruptive Technologies Innovation Fund administered by Enterprise Ireland.
TMC’s BioBridge program facilitates the exchange of ideas and research at a global scale to better the patient experience and provide groundbreaking solutions for complex health care problems. The TMC I Ireland BioBridge is TMC’s fourth international partnership. Other global partners include Australia, Denmark and the United Kingdom. Over 80% of TMC Innovation’s current HealthTech Accelerator cohort is composed of international companies, showing the reach of TMC’s international partnerships.
